ArticleJournal of inflammation research2026
The Joint Effect of C-Reactive Protein and Fibrinogen in Predicting Intracranial Hypertension of Cerebral Venous Sinus Thrombosis Patients.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Intracranial hypertension is the most common symptom of cerebral venous sinus thrombosis. Recent studies have indicated that both the coagulation and inflammation systems play roles in the occurrence and development of cerebral venous sinus thrombosis. Therefore, this study aimed to explore the individual and combined effects of coagulation-related biomarker [fibrinogen (FIB)] and inflammation-related biomarker [C-reactive Protein (CRP)] in predicting intracranial hypertension. Patients and Methods: We retrospectively and consecutively included 157 cerebral venous sinus thrombosis patients, who were divided into four groups according to the cut-offs of CRP and FIB by the receiver operating characteristics curves: low CRP low FIB, high CRP low FIB, low CRP high FIB and high CRP high FIB. Logistic regression models were used to compute the odds ratios and 95% confidence intervals for intracranial hypertension across the four subgroups. Results: Cerebral venous sinus thrombosis patients with intracranial hypertension had much higher CRP and FIB levels than those without intracranial hypertension did (all P<0.05). After adjusted by gender, age, modified Rankin scale, duration, headache, seizure, smoking, history of thrombosis and other risk factors, white blood cell, systemic immune-inflammation index and estimated glomerular filtration rate, patients in high CRP high FIB group were 5.286 (95% CI: 2.04-13.701, P=0.001) times more frequent to experience intracranial hypertension than those in low CRP low FIB group did. The addition of CRP and FIB to the basic model significantly improved discriminatory power for intracranial hypertension, as area under the curve increased from 0.692 (95% CI: 0.609-0.775, P<0.001) to 0.767 (95% CI: 0.692-0.843, P<0.001). Conclusion: Higher levels of both CRP and FIB are associated with an increased risk of intracranial hypertension following cerebral venous sinus thrombosis. The combination of CRP and FIB has a better predictive ability for intracranial hypertension in patients with cerebral venous sinus thrombosis than either CRP or FIB alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.